Tafluprost: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: January 30, 2026🚩 Report this page

Tafluprost

Prostaglandin Analogues

GB MHRA

Drug class: Prostaglandin Analogues
Availability: See label
Markets covered: 1
Products on record: 4

Overview

Tafluprost is an active pharmaceutical ingredient in the Prostaglandin Analogues group (S01EE). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	4	January 30, 2026

GBUnited Kingdom· MHRA

4 products

Uses

GBOfficial regulatory label· revised September 19, 2025[1]

Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension. As monotherapy in patients: o who would benefit from preservative free eye drops o insufficiently responsive to first line therapy o intolerant or contra-indicated to first line therapy.
As adjunctive therapy to beta-blockers. Saflutan is indicated in adults ≥ 18 years.

How to take

Drug interactions

Known interactions involving Tafluprost. Select one for details. This list is informational and not a complete interaction checker.

Bimatoprost Latanoprost Latanoprostene Bunod Travoprost Unoprostone

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL160580017 · revised September 19, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised September 19, 2025[1]

5%. The most frequently reported treatment-related adverse event was ocular hyperaemia. It occurred in approximately 13% of the patients participating in clinical studies with preserved tafluprost in Europe and the US. 4% of patients participating in the pivotal studies.
1% (13/320) of patients treated with tafluprost. The following undesirable effects related to treatment were reported during clinical trials with tafluprost in Europe and the US after a maximum follow-up of 24 months: Within each frequency grouping, adverse reactions are presented in order of decreasing frequency.
Nervous system disorders Common (≥1/100 to <1/10): headache Eye disorders Common (≥1/100 to <1/10): eye pruritus, eye irritation, eye pain, conjunctival/ocular hyperaemia, changes in eyelashes (increased length, thickness and number of lashes), dry eye, foreign body sensation in eyes, eyelash discolouration, erythema of eye lid, superficial punctate keratitis (SPK), photophobia, increased lacrimation, blurred vision, reduced visual acuity and increased iris pigmentation.
Uncommon (≥1/1,000 to <1/100): blepharal pigmentation, eyelid oedema, asthenopia, conjunctival oedema, eye discharge, blepharitis, anterior chamber cells, ocular discomfort, anterior chamber flare, conjunctival pigmentation, conjunctival follicles, allergic conjunctivitis and abnormal sensation in eye.
Not known (cannot be estimated from the available data): iritis/uveitis, lid sulcus deepened, macular oedema/cystoid macular oedema. Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.
Respiratory disorders Not known (cannot be estimated from the available data): exacerbation of asthma, dyspnea Skin and subcutaneous tissue disorders Uncommon (≥1/1,000 to <1/100): hypertrichosis of eyelid Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised September 19, 2025[1]

Before treatment is initiated, patients should be informed of the possibility of eyelash growth, darkening of the eyelid skin and increased iris pigmentation. Some of these changes may be permanent, and may lead to differences in appearance between the eyes when only one eye is treated.
The change in iris pigmentation occurs slowly and may not be noticeable for several months. g. blue-brown, grey-brown, yellow-brown and green-brown. The risk of lifelong heterochromia between the eyes in unilateral cases is obvious. There is a potential for hair growth to occur in areas where tafluprost solution comes repeatedly in contact with the skin surface.
There is no experience with tafluprost in neovascular, angle-closure, narrow-angle or congenital glaucoma. There is only limited experience with tafluprost in aphakic patients and in pigmentary or pseudoexfoliative glaucoma. Caution is recommended when using tafluprost in aphakic patients, pseudophakic patients with torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema or iritis/uveitis.
There is no experience in patients with severe asthma. Such patients should therefore be treated with caution.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations